CJC-1295 and Ipamorelin: Understanding the Growth Hormone Secretagogue Stack

Among the most widely referenced combinations in growth hormone (GH) research, CJC-1295 and Ipamorelin have established themselves as a canonical pairing. Each compound targets different but complementary mechanisms in the GH secretion pathway — and together, they produce a more physiologically nuanced growth hormone pulse than either compound alone.

This guide covers the biology behind both peptides, explains why researchers typically use them together, and provides practical information for researchers sourcing these compounds in Australia.

What Is CJC-1295 (Without DAC)?

CJC-1295 is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH) — the hypothalamic peptide that signals the pituitary gland to produce and release growth hormone. The "without DAC" designation (where DAC = Drug Affinity Complex) is important: the DAC version extends the peptide's half-life dramatically (up to 8 days) by binding to albumin. The non-DAC version, by contrast, has a shorter active window of approximately 30 minutes, which more closely mimics the natural pulsatile pattern of GHRH secretion.

For researchers interested in studying physiological GH pulse dynamics rather than sustained GH elevation, the without-DAC formulation is typically preferred.

Mechanism of Action

CJC-1295 (without DAC) binds to GHRH receptors on pituitary somatotroph cells, stimulating GH synthesis and secretion. Its effects are amplified when somatostatin (the natural inhibitor of GH release) is in a low phase — which is why timing relative to somatostatin cycling is a relevant variable in research protocols.

What Is Ipamorelin?

Ipamorelin is a selective Growth Hormone Secretagogue Receptor (GHSR) agonist — commonly called a ghrelin mimetic or GH secretagogue. It was developed in the 1990s and distinguished itself from earlier compounds in the same class (such as GHRP-2 and GHRP-6) by its highly selective action and clean side-effect profile.

Selectivity: Why It Matters in Research

Earlier GH secretagogues like GHRP-6 stimulated not only GH release but also significant increases in cortisol and prolactin — variables that confound research data when the aim is to study GH-specific effects. Ipamorelin's selective binding to GHSR-1a produces robust GH release with minimal cortisol and prolactin elevation, making it a cleaner research tool.

Why Combine CJC-1295 and Ipamorelin?

The rationale for combining CJC-1295 (without DAC) and Ipamorelin is rooted in physiology. Growth hormone secretion is regulated by two opposing signals:

1. GHRH — stimulates GH release (CJC-1295 mimics this)
2. Somatostatin — inhibits GH release (Ipamorelin partially overcomes this inhibition via the ghrelin pathway)

By simultaneously targeting both the stimulatory (GHRH) and ghrelin pathways, CJC-1295 + Ipamorelin produces a synergistic GH pulse that is typically larger and more sustained than either compound administered alone. Animal model research has demonstrated this additive effect clearly, and it forms the basis for the pairing's widespread use in research protocols.

What Does the Research Show?

In animal studies, CJC-1295 + Ipamorelin administration has been associated with:

• Significant increases in serum GH and IGF-1 levels
• Improvements in lean muscle mass in older subjects
• Reductions in adipose tissue, particularly visceral fat
• Enhanced recovery and tissue repair outcomes in wound healing models
• Improvements in sleep architecture in some rodent studies (consistent with GH's known role in slow-wave sleep)

Human data is more limited but includes small trials examining GH deficiency and age-related GH decline, with broadly positive metabolic outcomes reported.

CJC-1295 + Ipamorelin vs. Other Growth Hormone Peptides

Researchers sometimes compare the CJC-1295/Ipamorelin stack with other GH-related research compounds. Some key distinctions:

• AOD9604: Rather than stimulating GH release, AOD9604 is a fragment of the GH molecule itself, acting directly on adipose tissue to promote lipolysis. It does not significantly stimulate IGF-1. Useful for fat metabolism research without systemic GH elevation.
• MOTS-c: Acts on mitochondrial/AMPK pathways for metabolic regulation. Completely different mechanism to GH secretagogues — but may produce overlapping body composition effects via different routes. See the Mots-c 10mg product page for more information.

Sourcing CJC-1295 + Ipamorelin in Australia

Platinum Peptides offers a pre-combined formulation designed for research convenience: CJC-1295 w/out DAC 10mg + Ipamorelin 10mg. This combination vial provides both peptides in a single lyophilised preparation at equal concentrations, simplifying reconstitution and storage logistics for researchers running standard GH secretagogue protocols.

Handling and Storage

• Storage (lyophilised): -20°C for long-term; 4°C for up to 4 weeks.
• Reconstitution: Bacteriostatic water is standard. Both peptides are stable in aqueous solution when kept cold.
• Storage (reconstituted): 4°C; use within 28 days. Minimise freeze-thaw cycles.
• Light exposure: Keep vials away from direct light during both storage and reconstitution.

Frequently Asked Questions

What is the difference between CJC-1295 with DAC and without DAC?

The DAC (Drug Affinity Complex) modification extends CJC-1295's half-life from approximately 30 minutes to around 6–8 days by enabling albumin binding. The without-DAC version produces a shorter, more physiologically pulsatile GH release pattern, which is preferable for most research protocols studying GH dynamics. The with-DAC version produces a sustained elevation more suited to research designs requiring prolonged GH exposure.

Why is Ipamorelin preferred over GHRP-6 in modern research?

GHRP-6, while effective, stimulates significant increases in cortisol and prolactin alongside GH release. Ipamorelin is more selective for the GHSR-1a receptor and produces similar or superior GH release with minimal cortisol or prolactin effects, reducing confounding variables in research data.

Can CJC-1295 + Ipamorelin be studied alongside tissue repair peptides?

Yes — GH and its downstream mediator IGF-1 have well-established roles in tissue repair and regeneration. Combining GH secretagogue research with tissue repair peptides like BPC-157 10mg or the BPC-157 + TB500 combination is a logical research design for studying synergistic recovery mechanisms.

Conclusion

CJC-1295 (without DAC) and Ipamorelin represent a well-characterised, mechanistically complementary pairing for growth hormone research. Their combined action on the GHRH and ghrelin pathways produces a clean, amplified GH pulse that has made this combination one of the most studied in peptide science.

For Australian researchers, the CJC-1295 w/out DAC 10mg + Ipamorelin 10mg combination from Platinum Peptides provides a convenient, research-grade starting point — backed by domestic availability and competitive pricing.

Disclaimer: All products are supplied strictly for research purposes. Not intended for human consumption or therapeutic use.